|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Avandia-type crisis could hit other drugs
In this interview with Fred Hassan, CEO of ScheringPlough, Hassan argues that data transparency on the web is leading to an explosion of "questionable third party analysis."
Hassan, who is also president of the International Federation of Pharmaceutical Manufacturers and Associations, said the decision by companies to post their clinical trial results on the Internet increased the scope for sometimes questionable third-party analysis.
|home spotlight commentary research events news about contact links archives|